股票 
板块 
用户 
资讯 自身免疫疾病的药物研发，长期被一个现实问题卡着：传统小鼠模型很难真正"复刻"人体的免疫紊乱。以系统性红斑狼疮和ANCA相关性血管炎为例，B细胞异常活化、自身抗体沉积、肾脏损伤等环节环环相扣，想在临床前判断一个候选药到底有没有效，就必须借助更贴近人类病理的模型。
11月，全球领先的风湿病学学术舞台 ACR Convergence 2026将在美国佛罗里达州奥兰多举行。药康生物将带着三项针对性的模型研究，在奥兰治县会议中心（Orange County Convention Center）分享我们在自身免疫疾病临床前评价上的最新进展。会议时间为2026年11月6日至11日，以下成果均将在现场以壁报形式呈现。
01
三项模型，聚焦两大疾病方向
2026
不同于按日程罗列，我们把三项研究按所聚焦的疾病重新梳理：其中两项针对系统性红斑狼疮，一项针对ANCA相关性血管炎。
方向一：系统性红斑狼疮（SLE）
Poster Session B · Monday, November 9, 2026 · 10:30 a.m.–12:30 p.m.
0995
A Novel APRIL/BAFF Dual-Target Humanized Mouse Model of SLE for Preclinical Evaluation of Therapeutics Targeting APRIL/BAFF 用于临床前评价靶向APRIL/BAFF疗法的新型APRIL/BAFF双靶点SLE人源化小鼠模型
看点：B6-hAPRIL/hBAFF 双靶点人源化小鼠会自发出现SLE样症状。研究用已获批、同时阻断APRIL与BAFF的TACI-Fc融合蛋白telitacicept（泰它西普）进行验证，结果显示其可显著降低血清IgG、IgM、IgA及抗dsDNA自身抗体，降低浆细胞的比例与数量，并明显减少肾脏IgA沉积，为评价靶向APRIL/BAFF的新疗法提供了自发狼疮模型。
Poster Session B · Monday, November 9, 2026 · 10:30 a.m.–12:30 p.m.
1100
Application of a Human Immune System-Reconstituted Mouse Model of Lupus in Evaluating the Efficacy of B Cell-Targeting Therapies 人免疫系统重建狼疮小鼠模型在评价B细胞靶向疗法疗效中的应用
看点：研究向免疫缺陷的NCG-M/hIL15小鼠移植人造血干细胞（huHSC），再用TLR7/8激动剂Resiquimod诱导，重建出带狼疮表型的人免疫系统。CD20单抗rituximab（利妥昔单抗）与CD19 T细胞衔接器Blincyto（贝林妥欧单抗）均能清除外周血、脾脏和骨髓中的B细胞；Blincyto还显示出降低人抗dsDNA、总IgG以及肾脏IgG沉积的趋势。
方向二：ANCA相关性血管炎（AAV）
Poster Session C · Tuesday, November 10, 2026 · 10:30 a.m.–12:30 p.m.
1943
Establishment and Validation of a Mouse Model of ANCA Associated Vasculitis ANCA相关性血管炎小鼠模型的建立与验证
看点：研究用人髓过氧化物酶（MPO）诱导的血管炎模型，复现了尿白蛋白肌酐比（UACR）升高、肾小球新月体形成与炎症因子升高等特征。以地塞米松（dexamethasone）验证，可降低血清TNF-α、IL-1β，减少肾脏免疫细胞浸润，并缓解肾小球新月体、肾小球坏死及管间质炎症。
?? 以上时间均为美国奥兰多当地时间。
02
从模型到药效的一体化服务
2026
在自身免疫疾病方向，药康生物的能力并不止于单一模型。围绕基因工程小鼠、人源化小鼠和人免疫系统重建，我们把模型构建与体内药效、病理评价衔接起来，形成一条可贯通的临床前研究链条。针对狼疮、ANCA相关性血管炎等适应症，研究者可以在同一套体系内完成从靶点验证、候选药筛选到疗效与安全性评价的工作，让模型更贴近临床问题，也让研发决策更有依据。
03
现场1v1交流
2026
欢迎莅临壁报现场，与科学团队 Juan Liang、Yang Yu、Helen Xu、Xiaojing Ma 当面交流。如果你希望提前锁定一段深入讨论的时间，可发送邮件至 sales@gempharmatech.com 预约，我们会根据你的研究方向准备相应的模型与方案建议。
11月的奥兰多，期待与关注自身免疫疾病的研究者相遇。无论是一个具体的模型选择，还是一整套临床前评价方案，我们都希望这些更贴近人类疾病的模型，能帮你的药物走得更稳、更快。
A practical bottleneck has long held back autoimmune drug development: conventional mouse models rarely reproduce the full picture of human immune dysfunction. In diseases such as systemic lupus erythematosus and ANCA-associated vasculitis, abnormal B-cell activation, autoantibody deposition, and kidney injury are tightly linked. Determining whether a candidate drug truly works before the clinic therefore requires models that mirror human pathology more closely.
This November, at ACR Convergence 2026 in Orlando, Florida, GemPharmatech will present three model studies addressing exactly this challenge at the Orange County Convention Center from November 6 to 11, 2026. All three will be shared as on-site posters.
01
Three Models, Organized by Disease
2026
Rather than listing them by schedule, we have grouped the three studies by the disease they address—two for systemic lupus erythematosus and one for ANCA-associated vasculitis.
Track 1: Systemic Lupus Erythematosus(SLE)
Poster Session B · Monday, November 9, 2026 · 10:30 a.m.–12:30 p.m.
0995
A Novel APRIL/BAFF Dual-Target Humanized Mouse Model of SLE for Preclinical Evaluation of Therapeutics Targeting APRIL/BAFF
Highlight: B6-hAPRIL/hBAFF dual-target humanized mice spontaneously develop SLE-like phenotypes. Validated with telitacicept (TACI-Fc), an approved therapy that blocks both APRIL and BAFF, the model showed significant reductions in serum IgG, IgM, IgA, and anti-dsDNA autoantibodies, decreased plasma-cell proportions and numbers, and markedly reduced renal IgA deposition—offering a spontaneous lupus model for evaluating novel APRIL/BAFF-targeting therapies.
Poster Session B · Monday, November 9, 2026 · 10:30 a.m.–12:30 p.m.
1100
Application of a Human Immune System-Reconstituted Mouse Model of Lupus in Evaluating the Efficacy of B Cell-Targeting Therapies
Highlight: Human hematopoietic stem cells (huHSCs) engrafted into immunodeficient NCG-M/hIL15 mice, followed by TLR7/8 agonist (Resiquimod) induction, reconstituted a human immune system with lupus phenotypes. Both rituximab (CD20 mAb) and Blincyto/blinatumomab (CD19 T-cell engager) depleted B cells in peripheral blood, spleen, and bone marrow; Blincyto also showed a trend toward lower human anti-dsDNA and total IgG and reduced renal IgG deposition.
Track 2: ANCA-Associated Vasculitis(AAV)
Poster Session C · Tuesday, November 10, 2026 · 10:30 a.m.–12:30 p.m.
1943
Establishment and Validation of a Mouse Model of ANCA Associated Vasculitis
Highlight: Immunization with human myeloperoxidase (MPO) in complete Freund's adjuvant, followed by an anti-GBM antibody, created an MPO-induced vasculitis model that recapitulates elevated UACR, glomerular crescent formation, and increased inflammatory cytokines. Dexamethasone validation lowered serum TNF-α and IL-1β, reduced renal immune-cell infiltration, and alleviated crescents, glomerular necrosis, and tubulointerstitial inflammation.
All times are in Orlando local time (Eastern Time, ET).
02
What GemPharmatech Brings to
Autoimmune R&D
2026
Our capabilities in autoimmune disease extend well beyond any single model. Bringing together genetically engineered mice, humanized mice, and human immune system reconstitution, we connect model construction with in vivo efficacy and pathology evaluation into one continuous preclinical chain. Across lupus, ANCA-associated vasculitis, and other indications, researchers can move from target validation and candidate screening through efficacy and safety assessment within a single, clinically relevant framework.
03
How to Meet Us in Orlando
2026
Come to our poster sessions and meet Juan Liang, Yang Yu, Helen Xu, and Xiaojing Ma. To reserve a dedicated discussion in advance, email us at sales@gempharmatech.com, and we will prepare relevant model and program recommendations for your research direction. Whether you need help choosing one specific model or designing a full preclinical program, we hope these more human-disease-like models can help your therapy move forward with greater confidence. See you in Orlando.
作者｜Zoe
审核｜Kathy
编辑｜Kloe
就到这了，文末点个??给小编加个鸡腿吧~
扫码立刻享受1v1咨询！
关于药康生物
江苏集萃药康生物科技股份有限公司（科创板代码：688046）是一家专注于实验动物小鼠模型研发、生产及非临床研究服务的国家级高新技术企业，同时是科技部认定的国家遗传工程小鼠资源库共建单位。 依托CRISPR/Cas9、ES打靶等在内的基因编辑技术，公司建立了国际一流的基因修饰动物模型研发平台，拥有近3万种自主知识产权的基因工程小鼠模型品系，其中包括基因敲除/条件性敲除小鼠品系（"斑点鼠计划"）、药靶基因人源化模型、复杂疾病模型、系列免疫缺陷小鼠品系、无菌小鼠品系以及用于抗体药物发现的NeoMab?全人源抗体转基因小鼠，为全球科研机构、CRO公司及医药企业提供全面的模型资源支持。公司提供从基因编辑定制（包括转基因TG、基因敲除KO、基因敲入KI及点突变PM等）、模型繁育到功能药效分析的全流程一站式服务，服务范围涵盖肿瘤、自身免疫性疾病、代谢心血管疾病、神经退行性疾病、感染性疾病及罕见病等重点疾病领域，具体包括靶点验证、药效学评价和非GLP安全性评价等临床前研究。 药康生物致力于成为全球实验动物模型领域的领导者，通过持续深化基因编辑技术的创新应用和资源整合，为生命科学研究和生物医药产业提供高质量的动物模型和技术服务，推动人类健康事业发展。
点赞
收藏
分享
评论 (0)